Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aurinia Pharmaceuticals (AUPH) PT Raised to $15 at H.C. Wainwright
August 13, 2018 7:19 AM EDTH.C. Wainwright analyst Ed Arce raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $15.00 (from $12.00) while maintaining a Buy rating.
Arce comments "Under voclosporin's Fast Track designation,Aurinia is actively preparing the rolling NDA submission, with the first... More
